135 results about "Linagliptin" patented technology

The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.

The invention relates to antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia, inter alia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. The medication is a mono treatment with a DPP-4 inhibitor <preferably linagliptin> or a combination treatment with a DPP-4 inhibitor and a second and/or third antidiabetic.

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

The invention relates to a preparation method of Linagliptin. According to the preparation method, potassium carbonate or sodium carbonate is taken as an alkali; an iodine-containing inorganic salt is taken as a catalyst; N-methyl-2-pyrrolidone (NMP) or N,N-Dimethylformamide (DMF) is taken as a solvent; 8-bromo-7-(2-butynyl)-3,7-dihydro-3-methyl-1H-purine-2,6-dione is reacted with a (R)-3-aminopiperidine compound firstly at 40 to 50 DEG C; after reaction, 2-(chloromethyl)-4-methylquinazoline is directly added for reaction so as obtain a compound D; and the compound D is subjected to step 1-2 to prepare Linagliptin. The preparation method is capable of shortening reaction time, and increasing yield.

The invention discloses a linagliptin impurity as shown in a formula (I) which is described in the specification, a preparation method for the linagliptin impurity and application of the linagliptin impurity as an impurity reference substance for inspection of substance related to linagliptin. As the linagliptin impurity is applied as a standard reference substance, linagliptin quality can be effectively controlled, and security risks of a drug can be reduced, so security and validity of the linagliptin preparation in clinical application can be guaranteed.

The present invention discloses an improved process for preparing an important intermediate of linagliptin. In particular, disclosed are a process for preparing a compound V which is an important intermediate of linagliptin and has the structure V, and an industrial process of preparing linagliptin having excellent chemical and optical purities, which is an inhibitor of dipeptidyl peptidase-4 (DPP-IV), from the compound V. The process employs a phase-transfer catalyst, is high in yield, easy and simple to handle, environmentally friendly, suitable for industrial mass production, and can be implemented by a “one-pot process”.

The invention relates to the technical field of medicines and particularly relates to an industrial preparation process of linagliptin. The industrial preparation process comprises the steps of adding a reactant a (2-chloromethyl-4-methyl-quinazoline), an equal molar ratio of reactant b (8-bromo-7-(2-butynyl)-3-methylxanthine), an acid-binding agent and a proper amount of solvent into a reaction kettle to react at 0-140 DEG C for 3-8 hours, after TLC detection reaction is finished, directly adding a reactant c ((R)-3-phthalimide piperidine-tartaric acid) and an acid-binding agent, namely N,N-diisopropylethylamine without processing a reaction mother liquid to react at 0-125 DEG C for 3-10 hours, after the TLC detection reaction is finished, adding ethanolamine without processing the reaction mother liquid to react for 2-10 hours, after the TLC detection reaction is finished, dropwise adding purified water, carrying out suction filtration to obtain a linagliptin rough product, and refining by virtue of a refining method disclosed in a patent CN101437823A, so as to obtain a linagliptin refined product. According to the industrial preparation process, linagliptin is synthesized by virtue of a one-pot continuous feeding method, the consumption of the solvent is low, and the operation is easy; and the industrial preparation process is suitable for industrial production.

The invention relates to the area of medicinal chemistry, pharmacology and medicine and includes description of pharmaceutical compositions and combined medicaments on the base of secretion stimulators and protectors of incretin hormones for treatment of metabolic diseases (among them, diabetes, obesity, metabolic syndrome and the like). The invention consists in that that pharmaceutical composition or combined medicament comprises a derivative of tetrahydrobenzo[f][1,4]oxazepine—either nonsteroidal agonist of bile aids receptor TGR5, or one of endogenous bile acids which stimulate incretin hormones secretion, and also one of the known inhibitors of DPP-IV proteinase. In this case administration of TGR5 agonists is carried out peroral, and administration of endogenous bile acids is exercised rectal in the form of suppository or gel. As proteinase DPP-IV inhibitors could be used Vildagliptin, Saxagliptin, Sitagliptin, Teneligliptin, Linagliptin, Dutogliptin, Alogliptin, Gemigliptin, Carmegliptin and the like. Besides, the invention includes description of novel tetrahydrobenzo[f][1,4]oxazepine derivatives—nonsteroidal agonist of bile aids receptors TGR5, and also methods for their preparation. The invention provides enhancement of therapy effectiveness owing to synergetic action of the components, thus making possible simultaneous treatment of diabetes, and obesity, other metabolic diseases and their cardiovascular and renal complications.

The invention provides a compound disclosed as Formula I or a pharmaceutically acceptable salt thereof, and a preparation method and application thereof. The new compound provided by the invention can effectively inhibit dipeptidyl peptidase-IV (DPP-IV) activity with better effects than the existing DPP-IV enzyme inhibitor Linagliptin; and meanwhile, the compound has the advantages of higher selectivity for DPP-IV, higher safety and lower toxic or side effect on the DPP inhibitor, and thus, provides a new medicine option for treating or/and preventing diseases related to DPP-IV enzyme activity.

The invention belongs to the technical field of bulk drug preparation and particularly relates to an improvement in a preparation method for linagliptin. According to the preparation method for linagliptin, the particle diameter of an acid-binding agent anhydrous sodium carbonate used in a linagliptin two-step condensation reaction is controlled on a micron order, an iodide catalyst is not needed during the reaction, similarly, the reaction temperature is decreased, reaction time is shortened, the two-step reaction is changed into a one-pot reaction, and a key intermediate E compound with high purity and yield is prepared. The preparation method is suitable for industrial mass production of linagliptin, and finally linagliptin with high purity and yield is obtained.

The present invention relates to processes for the preparation of 8-(3R)-3-aminopiperidinyl)-7-butyn-2-yl-3 -methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione and novel intermediates useful in its synthesis.

The invention relates to solid pharmaceutical dosage forms comprising an extended release core comprising metformin hydrochloride and one or two immediate release coatings comprising linagliptin and/or empagliflozin.

The invention relates to a simple preparation method of high-purity linagliptin. The method includes the steps of making 8-bromine-3-methyl xanthine and 1-bromo-2-butyne react, directly adding 2-chloromethyl-4-methylquinazoline without processing after reaction is completed, preparing a key intermediate 8-bromine-7-(2-butyne-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-diketone of linagliptin through a one-pot method, making the intermediate react with (R)-3-piperidinamine dihydrochloride after being filtered and separated to obtain a linagliptin solution, and obtaining a linagliptin pure product after processing the linagliptin solution. The key intermediate is prepared through the one-pot method, operation is convenient, and yield is increased; the key intermediate reacts with (R)-3-piperidinamine dihydrochloride after being separated, and therefore high-purity linagliptin is obtained, and the requirements for production and declaration of pharmaceutical enterprises are met to the maximum extent.

The invention discloses linagliptin particles and a preparation method thereof. Linagliptin is used for treating type 2 diebetes. At present, only linagliptin tablets are sold on the market. Aiming at dysphagia patients, compared with the above two dosage forms, the linagliptin particles have obvious advantages and can improve drug compliance of patients.

The invention discloses a pharmaceutical composition containing a dipeptidyl peptidase IV inhibitor linagliptin, use and preparation method thereof. The linagliptin containing pharmaceutical composition provided by the invention consists of linagliptin or a salt thereof serving as the active ingredient, and pharmaceutical excipients mannitol, pregelatinized starch, corn starch and magnesium stearate. The linagliptin containing pharmaceutical composition provided by the invention reduces the types of excipients, increases the stability of the preparation, reduces the cost of raw materials, and solves the hardness and friability problems of linagliptin tablets by controlling the particle size of the key excipient mannitol. The obtained table has all indicators especially the dissolution rate in line with the drug quality standards, and the process is simple, thus being more suitable for large scale production.

The invention discloses a linagliptin new crystal form and a preparation method thereof, belonging to the technical field of medicinal chemistry. X-ray powder diffraction, infrared analysis, melting point measurement, differential scanning calorimetry, thermogravimetric analysis, and nuclear magnetic resonance are performed on the new crystal form. The linagliptin new crystal form is obviously different from the linagliptin crystal form in the prior art. The new crystal form has good chemical stability and crystal form purity, is easy to prepare in a large scale, is simple to operate, and has a broad application prospect.

The invention relates to a method for converting dimers of linagliptin into linagliptin. Under the alkaline condition that the pH value is not less than 8, dimers can be converted into a product linagliptin under the action of alkali, so that impurities are removed, and the yield is increased. The method is simple in process, reduces the production cost, and facilitates the industrial production.

The invention discloses a preparation method of linagliptin. The preparation method comprises putting t-butyloxycarbonyl-linagliptin (g) into a methanol aqueous solution and carrying out stirring so that the solution undergoes a reaction along with heating reflux in an inert atmosphere at a temperature of 25-50 DEG C for 3-12h, wherein a weight ratio of the t-butyloxycarbonyl-linagliptin (g) to the methanol aqueous solution is 100: (400-550). The preparation method carries out Boc protection base removal in a methanol aqueous solution in an inert gas protective atmosphere, is free of expensive trifluoroacetic acid-DCM in a Boc protection base removal reaction, only utilizes a cheap methanol-water system and has simple after-treatment processes. A trifluoroacetic acid-DCM system reaction produces more impurities and needs a very complex post-treatment purifying process. The preparation method prevents strong acid-produced intermediate (g) impurities and linagliptin amide bond fracture impurities.

The present invention discloses a high performance liquid chromatography method for simultaneous determination of linagliptin and metformin contents, a reverse-phase high performance liquid chromatography method is used, a to-be-tested solution and a contrast solution are prepared, 10mul of the to-be-tested solution and 10mul of the contrast solution are respectively taken by measuring, and injected into a chromatographic instrument, chromatogram is recorded, and determination of linagliptin and metformin contents can be completed by peak area calculation and conversion into dry content by external standard method; the advantages of the method are that: the method fills the blank of no analysis method for determination of linagliptin and metformin contents in the prior art, can satisfy the needs of research and development and production, and provides the necessary technical support for linagliptin drug to come into the market early.

An industrial production method of linagliptin. According to the molar ratio, 8-bromo-7-(2-butyne)-3-methylxanthine and 2-chloromethyl-4-methylquinazoline are added to the dipolar aprotic organic solvent, and then the base is added and potassium iodide, crystallized, filtered and dried to obtain intermediate I; according to the molar ratio, intermediate I and (R)-3-tert-butoxycarbonylaminopiperidine were added to the dipolar aprotic organic solvent, and alkali was added to analyze crystallized, filtered and washed to remove inorganic salts, and the solvent was removed under reduced pressure to obtain the crude product, which was then crystallized from methanol and isopropanol to obtain intermediate II; according to the volume ratio, intermediate II and the deprotection reagent were added to the reaction solvent, and crystallized to obtain The crude product was recrystallized with ethanol, filtered and dried to obtain the final product of linagliptin. The method of the invention can greatly shorten the production cycle, save production cost, obtain intermediates with higher purity, and better effect of removing impurities. The method is safe, reliable, simple and easy to operate, and has good repeatability.

The invention discloses a stable linagliptin medicine composition and a preparation method thereof. According to the formula, besides active components, through selection on a diluent and a disintegrating agent in special composition with ratio of all components being controlled, the linagliptin has excellent stability and bioavailability.